Impact of Local Biopsy to the Endometrium Prior to Controlled Ovarian Stimulation on Clinical Pregnancy (NIDABRECHE)

April 7, 2015 updated by: University Hospital, Bordeaux

Influence of Local Biopsy of the Endometrium Prior to Controlled Ovarian Stimulation for IVF or ICSI Procedure on the Rates of Embryo Implantation, Clinical Pregnancy and Live Birth in ART

In vitro fertilization (IVF) is the only available solution for many couples with various forms of infertility. The embryo implantation step in the IVF procedure is a complex multistage process and represents the majority of the causes of the IVF failure. Several approaches have been evaluated to improve implantation rates but none has demonstrated its superiority. However, endometrial receptivity is important for pregnancy and several studies suggest that local injury to the endometrium of IVF patients improves the rates of embryo implantation, clinical pregnancy and live birth.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

They are possible mechanisms by which endometrial sampling may increase receptivity and improve clinical pregnancy rate of IVF-ET. First, local injury to proliferative phase endometrium might induce the decidualization of the endometrium, and increase its implantation rate. Second, local injury to the endometrium might provoke the wound healing, involving a mass secretion of different cytokines and growth factor, which are beneficial for embryo implantation. Last, the injury might make the endometrium maturation.

This study proposes to evaluate the efficiency of an endometrial injury in the first controlled ovarian hyperstimulation cycle on the rate of clinical pregnancy, in assisted reproductive technologies. This study will compare 2 groups of patients. The first group will undergo biopsy of the endometrium before the IVF; the second will undergo the IVF alone. Inclusions will be conducted on 33 months; the patients will be in the study for a period of 36 weeks. The total duration of the study is 39 months

Study Type

Interventional

Enrollment (Actual)

190

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33075
        • CHU de Bordeaux, Hôpital Saint André, service de chirurgie gynécologie et médecine de la reproduction
      • Pessac, France, 33600
        • Cabinet Médical de gynécologie
      • Toulouse, France, 31059
        • CHU de Toulouse, service de médecine et biologie de la reproduction

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 38 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • primary or secondary infertility
  • first or second IVF attempt
  • aged ≥18 and ≤38 years
  • regular menstrual cycles
  • FSH≤ 12IU/L
  • Informed consent signed

Exclusion Criteria:

  • ovocyte donor
  • pathology of the uterus or annexes
  • Body mass index (BMI)> 35
  • ongoing vaginal infection
  • undetermined vaginal bleeding
  • contraindication to the Cornier pipette or to these treatments : Gonal F®, Puregon®, Ovitrelle®, Utrogestan®,
  • women included in another study on medically assisted procreation
  • any administrative or legal supervision

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group 1 : IVF with biopsy
fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF

The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:

  • Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.
  • Insert carefully the pipelle de Cornier® in the uterus through the cervix.
  • Withdraw the piston to create a negative pression
  • Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several "in and out" cycle in order to collect a complete sample of the endometrium.
  • Withdraw the pipelle de Cornier® when filled with tissue
  • Reinsert internal piston to deposit sample in cup filled with a fixative.
Active Comparator: group 2
fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of clinical pregnancy
Time Frame: 5 weeks after the embryo implantation in an IVF procedure
5 weeks after the embryo implantation in an IVF procedure

Secondary Outcome Measures

Outcome Measure
Time Frame
Rate of clinical pregnancy
Time Frame: 3 months after the IVF implantation
3 months after the IVF implantation
Rate of embryo implantation
Time Frame: 5 weeks after the embryo implantation
5 weeks after the embryo implantation
Rate of miscarriage/extra-uterine pregnancy/multiple pregnancy
Time Frame: first trimester after the IVF
first trimester after the IVF
Adverse effects during the local injury (biopsy) to the endometrium
Time Frame: during the biopsy
during the biopsy
Evaluation of the patients pain intensity and type from the biopsy.
Time Frame: during and after the biopsy
during and after the biopsy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Antoine Benard, Doctor, University Hospital Bordeaux, France
  • Principal Investigator: Sandrine Blancpain, Doctor, University Hospital Bordeaux, France

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2010

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

February 5, 2010

First Submitted That Met QC Criteria

February 5, 2010

First Posted (Estimate)

February 8, 2010

Study Record Updates

Last Update Posted (Estimate)

April 8, 2015

Last Update Submitted That Met QC Criteria

April 7, 2015

Last Verified

April 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2009/12

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary or Secondary Infertility

Clinical Trials on biopsy

3
Subscribe